{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [3, 5], "question": "How did the adjusted EBITDA change from 2022 to 2023 for both the Degree Program Segment and the Alternative Credential Segment?", "prediction": "The adjusted EBITDA for the Degree Program Segment increased from $180,727 in 2022 to $214,699 in 2023, representing an increase of 19%. The Alternative Credential Segment's adjusted EBITDA improved from a loss of $55,646 in 2022 to a loss of $43,903 in 2023, representing a 21% decrease in loss.", "ground_truth": "The adjusted EBITDA for the Degree Program Segment increased by $34 million from $180.7 million in 2022 to $214.7 million in 2023, while the Alternative Credential Segment's negative adjusted EBITDA improved by $11.7 million from -$55.6 million in 2022 to -$43.9 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [1, 4], "question": "How did the level of impairment charges for goodwill change in the Degree Program Segment and Alternative Credential Segment from 2022 to 2023?", "prediction": "In 2022, the Company recorded impairment charges of $28.8 million and $30.0 million to goodwill and the indefinite-lived intangible asset, respectively, in the first quarter, and $50.2 million and $29.3 million to goodwill and the indefinite-lived intangible asset, respectively, in the third quarter. In 2023, the Company recorded impairment charges of $16.7 million to goodwill and $117.4 million to the indefinite-lived intangible asset in the second quarter, and $62.8 million to goodwill in the fourth quarter, all related to the Alternative Credential Segment.", "ground_truth": "In the Degree Program Segment, there were no impairment charges for goodwill in either 2022 or 2023, whereas in the Alternative Credential Segment, goodwill impairment charges increased from $78.991 million in 2022 to $79.471 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [0, 3], "question": "How did Full Course Equivalent (FCE) enrollments change in both the Degree Program Segment and the Alternative Credential Segment from 2022 to 2023?", "prediction": "FCE enrollments in the Degree Program Segment decreased by 16.7% from 233,635 to 194,574, while FCE enrollments in the Alternative Credential Segment increased from 93,471 to 97,647.", "ground_truth": "FCE enrollments decreased by 16.7% in the Degree Program Segment from 233,635 in 2022 to 194,574 in 2023, while they increased by 4.5% in the Alternative Credential Segment from 93,471 in 2022 to 97,647 in 2023."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 2], "question": "What were the main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021?", "prediction": "The main factors contributing to the decline in gross profit were divestitures, cost inflation, and supply chain pressures.", "ground_truth": "The decline in gross profit for 3D Systems Corporation in 2022 compared to 2021 was primarily due to divestitures, lower sales volumes in the dental market, and inflationary cost pressures, as indicated by the financial data provided."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [2, 5], "question": "How did the impairment charges on property and equipment and the amortization expense related to intangible assets change from 2021 to 2022?", "prediction": "The impairment charges on property and equipment decreased from $788 in 2021 to $18 in 2022. Amortization expense related to intangible assets increased from $10,469 in 2021 to $15,480 in 2022.", "ground_truth": "The impairment charges decreased from $788,000 in 2021 to $18,000 in 2022, while amortization expense increased from $10,469,000 in 2021 to $15,480,000 in 2022."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 1], "question": "How did the operating income for Healthcare Solutions and Industrial Solutions segments change from 2021 to 2022?", "prediction": "The operating income for Healthcare Solutions decreased from $69.4 million in 2021 to $25.8 million in 2022, and the operating income for Industrial Solutions decreased from $48.6 million in 2021 to $22.8 million in 2022.", "ground_truth": "The operating income for Healthcare Solutions decreased by $43.5 million from $69.4 million in 2021 to $25.9 million in 2022, while for Industrial Solutions it decreased by $25.7 million from $48.6 million in 2021 to $22.8 million in 2022."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [2, 4], "question": "How much interest income did Block, Inc. earn from customer funds in 2023, and how did it compare to the previous years?", "prediction": "Block, Inc. earned interest income of $153.5 million from customer funds in 2023, which was immaterial in 2022 and 2021.", "ground_truth": "In 2023, Block, Inc. earned $153.5 million in interest income from customer funds, which was immaterial in both 2022 and 2021."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 2], "question": "How did the organizational structure change with respect to Block, Inc's management reporting in the fourth quarter of 2023 affect the allocation of BNPL platform financial results?", "prediction": "The organizational structure change moved the business activities and management of the BNPL platform fully under the Cash App segment, resulting in the financial results of the BNPL platform being solely reported within the Cash App segment, rather than being split between the Cash App and Square segments.", "ground_truth": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure, moving the business activities and management of its BNPL platform fully under the Cash App segment, thus ceasing the previous practice of allocating 50% of revenue and gross profit from the BNPL platform to both the Square and Cash App segments."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 4], "question": "How did the classification of consumer receivables and their allowance for credit losses change from January 31, 2022 to December 31, 2023?", "prediction": "The classification of consumer receivables and their allowance for credit losses remained consistent from January 31, 2022 to December 31, 2023, as they were classified as held for investment and accrued at amortized cost, adjusted for unearned merchant fees, origination costs, charge-offs, and the allowance for credit losses.", "ground_truth": "The consumer receivables classified as 'Pass' increased to $2.5 billion with $185.275 million in credit loss allowance by December 31, 2023, from the time of Afterpay's acquisition in January 2022 where the beginning allowance was $115.552 million."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [4, 5], "question": "What was the percentage change in the net property and equipment values for C.H. Robinson Worldwide, Inc. between December 31, 2022, and December 31, 2023?", "prediction": "The net property and equipment value decreased by 9.3% from $159,432 in 2022 to $144,718 in 2023.", "ground_truth": "The net property and equipment values decreased by approximately 9.2% from $159,432,000 on December 31, 2022, to $144,718,000 on December 31, 2023."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [1, 3], "question": "What were the primary factors affecting C.H. Robinson's financial performance in 2023 as indicated in the financial statements?", "prediction": "The primary factors affecting C.H. Robinson's financial performance in 2023 included a decline in transportation rates, weak freight demand, and excess carrier capacity in the surface transportation and global forwarding markets, resulting in lower revenues and adjusted gross profits.", "ground_truth": "C.H. Robinson's financial performance in 2023 was primarily affected by weak freight demand and excess carrier capacity leading to reduced net income and operating cash flow, alongside declines in transportation rates."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [3, 4], "question": "How did the revenue recognition policy related to in-transit shipments change from December 31, 2022, to December 31, 2023?", "prediction": "According to the financial statement, the revenue recognized for in-transit shipments at period end declined significantly at December 31, 2023, compared to December 31, 2022. This decline was driven by the change in the macroeconomic and industry factors impacting the cost of purchased transportation.", "ground_truth": "The revenue for contracts where the transit period was partially complete declined from $257.6 million at December 31, 2022, to $189.9 million at December 31, 2023, due to macroeconomic and industry factors impacting transportation costs."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 5], "question": "What was the total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, and how does it compare to the unrecognized compensation cost related to non-vested stock-based compensation arrangements as of the same date?", "prediction": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was approximately $231.3 million. This expense is significantly lower than the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements as of December 31, 2023, which is approximately $354.8 million, indicating that the Company has a substantial amount of compensation costs that have not yet been recognized.", "ground_truth": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231.3 million, while the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 4], "question": "How did the research and development expenses change from 2022 to 2023 compared to sales and marketing expenses, and what were the main reasons for these changes?", "prediction": "Research and development expenses increased by $32.5 million from 2022 to 2023. The main reasons for this change were increases in personnel expenses and facility and support services, as well as decreases in direct research and development costs for the BLUE-C clinical trial. In contrast, sales and marketing expenses decreased by $118.9 million from 2022 to 2023, primarily due to decreases in direct marketing costs and professional fees, as well as decreases in personnel expenses and facility and support services.", "ground_truth": "Research and development expenses increased by $32.5 million due to higher personnel expenses and facility costs, while sales and marketing expenses decreased by $118.9 million primarily due to reduced marketing costs and a realignment of the sales force."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [1, 3], "question": "How did Exact Sciences Corporation’s cash and cash equivalents at the end of 2023 compare with their amount at the beginning of the year, and what was the cause of this change based on their cash flow activities?", "prediction": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million at the end of 2023. This increase was primarily due to their cash flows from operating activities, which showed a positive increase of $156.1 million, as well as proceeds from financing activities, including a $138 million issuance of convertible notes. These positive cash flows and financing proceeds more than offset the cash used in investing activities, such as purchases of property, plant, and equipment, resulting in a net increase in cash and cash equivalents for the year.", "ground_truth": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million by the end of the year, driven by positive net cash provided by operating activities and an increase in net cash provided by financing activities, including proceeds from the issuance of convertible notes."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 1], "question": "How much did Esperion's net product sales increase from 2022 to 2023, and how much did their collaboration revenue increase within the same period?", "prediction": "The net product sales increased by 22.5 million from 55.9 million in 2022 to 78.3 million in 2023, representing a 22.1% or 22.5 million increase. The collaboration revenue increased by 18.4 million from 19.6 million in 2022 to 38.0 million in 2023, representing a 94% increase.", "ground_truth": "Esperion's net product sales increased from $55.9 million in 2022 to $78.3 million in 2023, while their collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [1, 4], "question": "How did Esperion Therapeutics, Inc.'s net loss change from 2022 to 2023 and what were the factors contributing to this change?", "prediction": "Esperion Therapeutics, Inc.'s net loss decreased by $24.4 million from $233.7 million in 2022 to $209.2 million in 2023. The decrease in net loss was primarily driven by an increase in net product sales and collaboration revenue, as well as a decrease in research and development expenses. Additionally, the increase in selling, general, and administrative expenses, including legal costs, was partially offset by higher interest income. These factors contributed to the change in Esperion Therapeutics, Inc.'s net loss from 2022 to 2023.", "ground_truth": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023, primarily due to increased net product sales and collaboration revenue, partially offset by increased selling, general, and administrative expenses."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 2], "question": "What changes occurred in the net product sales of NEXLETOL and NEXLIZET from 2022 to 2023, and how did the collaboration revenue compare during the same period?", "prediction": "The net product sales of NEXLETOL and NEXLIZET increased by approximately $22.4 million, from $55.9 million in 2022 to $78.3 million in 2023. Collaboration revenue also increased, from $19.6 million in 2022 to $38.0 million in 2023, representing an increase of $18.4 million.", "ground_truth": "Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, while collaboration revenue also grew from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [2, 5], "question": "What was the percentage change in the Company's total revenue from the Property & Casualty insurance vertical from 2021 to 2023, compared to the Health insurance vertical for the same period?", "prediction": "According to the 10-K filing, in 2022, the Property & Casualty insurance vertical accounted for $417,715,000 in revenue, and in 2023, it accounted for $164,234,000 in revenue, representing a decrease of 60.7%. In contrast, the Health insurance vertical accounted for $176,459,000 in revenue in 2021, and $186,275,000 in revenue in 2023, representing an increase of 5.6% from 2022, but a decrease of 5.8% from 2021 to 2023 for the P&C vertical and an increase of 5.9% for the health vertical.", "ground_truth": "The Company's total revenue from Property & Casualty insurance vertical decreased by 60.7% from $417,715,000 in 2021 to $164,234,000 in 2023, while the Health insurance vertical saw a 5.6% increase from $176,459,000 in 2021 to $186,275,000 in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [0, 5], "question": "How did the revenue from Open Marketplace transactions compare to Private Marketplace transactions in the year ended December 31, 2023?", "prediction": "The revenue generated from Open Marketplace transactions in the year ended December 31, 2023, was $378.7 million, whereas the Private Marketplace transactions generated $214.7 million in revenue, but the Private Marketplace revenue represents a platform fee billed to suppliers or demand partners based on an agreed-upon percentage of the Transaction Value, which was $9.4 million.", "ground_truth": "In the year ended December 31, 2023, Open Marketplace transactions generated $378,730,000 in revenue, which was significantly higher than Private Marketplace transactions which generated $9,419,000."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [3, 4], "question": "How did the decrease in P&C insurance revenue contribute to the overall decline in total revenue for the year ended December 31, 2023 compared to 2022?", "prediction": "The decrease in P&C insurance revenue from $224.4 million to $164.2 million resulted in a decline of 26.8% year-over-year and contributed to a 15.4% decline in total revenue from $459.1 million to $388.1 million for the year ended December 31, 2023 compared to 2022.", "ground_truth": "The P&C insurance revenue decreased by $60.1 million in 2023, primarily due to reduced customer acquisition spending by P&C carriers, contributing significantly to the overall decline in total revenue by $70.9 million compared to 2022."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [2, 4], "question": "What are the potential effects of regulatory changes on Mind Medicine's EU operations concerning data exclusivity and medical device regulations?", "prediction": "Regulatory changes in the EU, such as the proposed reduction of data exclusivity from 8 to 6 years, may impact Mind Medicine's ability to protect its intellectual property and maintain market exclusivity for its products. Additionally, changes to medical device regulations, including the implementation of the Medical Device Regulation (MDR), may require Mind Medicine to adapt its manufacturing and commercialization strategies to ensure compliance with new requirements.", "ground_truth": "Regulatory changes in the EU, such as the proposal to reduce data exclusivity from eight to six years and the MDR governing medical devices, could affect Mind Medicine's product development timelines and compliance requirements, impacting their ability to market products efficiently in the EU."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [3, 4], "question": "Between December 31, 2022, and December 31, 2023, how much of the equity securities registered under the shelf registration statement was issued by the company?", "prediction": "$40.2 million of equity securities were issued.", "ground_truth": "Between December 31, 2022, and December 31, 2023, the company issued $0.2 million of equity securities, as the availability decreased from $100.0 million to $99.8 million."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [1, 3], "question": "What are some potential consequences mentioned in the financial statements if the company fails to comply with controlled substance laws and regulations when developing its product candidates?", "prediction": "Some potential consequences mentioned include: enforcement actions, fines, penalties, loss of registrations, interruptions to development activities, and business continuity issues.", "ground_truth": "Failure to comply with controlled substance laws and regulations may result in increased costs, enforcement actions, regulatory scrutiny, potential litigation, and criminal prosecution, which could delay or prevent product development and commercialization."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [0, 2], "question": "What percentage of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer within the Compute & Networking segment, and what challenges does this concentration pose?", "prediction": "13% of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer within the Compute & Networking segment. This concentration poses challenges, such as the risk of losing this customer or a reduction in their demand, which could significantly impact NVIDIA's revenue. Additionally, the loss of this customer could lead to excess inventory or require NVIDIA to find alternative customers, which could be difficult due to the specialized nature of their products.", "ground_truth": "Sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, posing challenges like potential revenue impact from losing or being unable to sell to such major customers due to trade restrictions."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 5], "question": "What was the change in NVIDIA's net income from January 29, 2023, to January 28, 2024, and how does this compare to the change in revenue for the same period?", "prediction": "The net income increased by $25.4 billion (or 581%) from $4.4 billion to $29.8 billion. Revenue increased by $34 billion (or 126%) from $27 billion to $60.9 billion. The percentage increase in net income (581%) was greater than the percentage increase in revenue (126%).", "ground_truth": "NVIDIA's net income increased from $4.37 billion on January 29, 2023, to $29.76 billion on January 28, 2024, while revenue increased from $26.97 billion to $60.92 billion during the same period."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 2], "question": "What percentage of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment, and how does this demonstrate a risk presented in the Risk Factors?", "prediction": "13% of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment. This demonstrates the risk presented in the Risk Factors section, specifically the risk that the company's revenue is concentrated among a limited number of customers, and the loss of one of these customers could significantly impact the company's financial performance.", "ground_truth": "In fiscal year 2024, 13% of NVIDIA's revenue came from a single customer in the Compute & Networking segment, illustrating the risk of revenue concentration from limited partners and distributors, as mentioned in the Risk Factors."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [1, 3], "question": "How did Paratek's financial position affect their ability to utilize net operating loss carryforwards after the merger, and what was the impact on regulatory operations?", "prediction": "Following the merger involving Transcept Pharmaceuticals and Paratek Pharmaceuticals in 2014, Paratek incurred significant losses from operations, resulting in accumulated deficits of $930.4 million through December 31, 2022. The company generated net product revenue of $136.8 million and a net loss of $63.6 million for the fiscal year 2022. Paratek is unable to utilize its net operating loss carryforwards due to ownership change limitations under Sections 382 and 383 of the Internal Revenue Code of 1986.", "ground_truth": "Paratek's financial position was impacted by ownership changes from the merger that limited the use of net operating loss carryforwards, which could materially affect cash flow and operations as government regulations require cost compliance in various areas."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [3, 4], "question": "How did the full-year net product revenue change for Paratek Pharmaceuticals' NUZYRA from 2021 to 2022, and what was the impact on the company's net loss for the same period?", "prediction": "Paratek Pharmaceuticals' full-year net product revenue for NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, resulting in an increase of $30.7 million. This increase contributed to a larger net loss of $63.6 million in 2022, compared to a net loss of $59.1 million in 2021, as the company's total operating expenses also increased.", "ground_truth": "The net product revenue for Paratek Pharmaceuticals' NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, while the net loss increased from $59.1 million in 2021 to $63.6 million in 2022."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [0, 2], "question": "What are the factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements?", "prediction": "The commercialization success of NUZYRA in the U.S. is dependent on several factors including the ability to educate and increase physician awareness of the benefits, safety, and cost-effectiveness of NUZYRA, as well as the acceptance of NUZYRA by physicians, patients, and the medical community. Additionally, the success of NUZYRA will depend on the company's ability to secure widespread acceptance of the product, demonstrate its effectiveness in treating serious and community-acquired bacterial infections, and provide a cost-effective treatment option. Furthermore, the company's commercialization efforts are subject to various risks and uncertainties associated with product sales, government and payor restrictions, and healthcare Fabian reform and other changes in the healthcare system. The company must also navigate the complexities of the U.S. healthcare system, obtain sufficient funding, and execute its business strategy effectively to achieve commercial success.", "ground_truth": "The success of NUZYRA's commercialization in the U.S. depends on securing starting materials, maintaining manufacturing arrangements, producing sufficient quantities, building sales and marketing capabilities, gaining product acceptance, obtaining sufficient reimbursement, and maintaining compliance with FDA requirements as mentioned in the financial statements."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 2], "question": "What were the factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023?", "prediction": "The change in automotive sales revenue and gross margin from 2022 to 2023 was primarily due to an increase of 473,382 combined Model 3 and Model Y cash deliveries, partially offset by a lower average selling price on vehicles driven by overall price reductions, sales mix, and foreign exchange rates. The gross margin decrease was primarily due to the lower average selling price, partially offset by a favorable change in the average combined cost per unit of vehicles, IRA manufacturing credits earned, and sales mix.", "ground_truth": "Automotive sales revenue increased by $11.30 billion due to a rise in Model 3 and Model Y deliveries, while the gross margin decreased from 28.5% to 19.4% due to lower average selling prices and increased costs."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [3, 5], "question": "How did Tesla's short-term investments and inventory change from December 31, 2022, to December 31, 2023?", "prediction": "According to the financial statements, Tesla's short-term investments increased from $5.932 billion to $12.696 billion, and inventory increased from $12.839 billion to $13.626 billion, from December 31, 2022, to December 31, 2023.", "ground_truth": "Tesla's short-term investments increased from $5,932 million in 2022 to $12,696 million in 2023, while inventory increased from $12,839 million in 2022 to $13,626 million in 2023."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 5], "question": "How do the commitments for capital expenditure and tax revenues in the state of New York compare to those in Shanghai, China for Tesla as of December 31, 2023?", "prediction": "As of December 31, 2023, Tesla had committed to spending $5.00 billion in combined capital, operational expenses, costs of goods sold, and other costs in the state of New York through December 31, 2029, and had met the annual requirements for jobs and investment in Buffalo and New York State. In Shanghai, China, Tesla had committed to spending RMB 14.08 billion in capital expenditures by the end of 2023, which had been achieved, and to generating RMB 2.23 billion of annual tax revenues starting at the end of 2023, which it expects to meet based on its current level of spend and sales.", "ground_truth": "As of December 31, 2023, Tesla committed to $5 billion in combined expenditures and costs in New York state by the end of 2029, while in Shanghai, China, Tesla committed to RMB 14.08 billion in capital expenditures and RMB 2.23 billion in annual tax revenues by the end of 2023, both of which have been achieved."}
